Abstract: Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to express a mutant AROM polypeptide and/or mutant catechol-O-methyltransferase polypeptide alone or in combination with one or more vanillin biosynthetic enzymes or UDP-glycosyltransferases (UGTs). Such microorganisms, plants, or plant cells can produce vanillin or vanillin beta-D-glucoside.

Abstract: Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to express a mutant AROM polypeptide and/or mutant catechol-O-methyltransferase polypeptide alone or in combination with one or more vanillin biosynthetic enzymes or UDP-glycosyltransferases (UGTs). Such microorganisms, plants, or plant cells can produce vanillin or vanillin beta-D-glucoside.

Abstract: The present invention provides 2-Methyl-amino-3-[(4-fluorophenyl)carbonyl]indolizine-1-carboxamide of formula (I) or a pharmaceutically acceptable salt thereof; and its therapeutic uses in the treatment of neurodegenerative disorders, in particular tauopathies and most preferably in the treatment of Alzheimer's disease.

Abstract: Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to express a mutant AROM polypeptide and/or mutant catechol-O-methyltransferase polypeptide alone or in combination with one or more vanillin biosynthetic enzymes or UDP-glycosyltransferases (UGTs). Such microorganisms, plants, or plant cells can produce vanillin or vanillin beta-D-glucoside.

Abstract: Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to express a mutant AROM polypeptide and/or mutant catechol-O-methyltransferase polypeptide alone or in combination with one or more vanillin biosynthetic enzymes or UDP-glycosyltransferases (UGTs). Such microorganisms, plants, or plant cells can produce vanillin or vanillin beta-D-glucoside.

Abstract: The present disclosure provides methods for identifying anthocyanins with improved stability, color, or hue using a screening method, and producing anthocyanins with improved stability, color, or hue in, for example, host cells comprising one or more heterologous glycosyltransferase nucleic acid molecules and one or more heterologous acyltransferase nucleic acid molecules.

Abstract: The present invention provides 2-Methyl-amino-3-[(4-fluorophenyl)carbonyl]indolizine-1-carboxamide of formula (I) or a pharmaceutically acceptable salt thereof; and its therapeutic uses in the treatment of neurodegenerative disorders, in particular tauopathies and most preferably in the treatment of Alzheimer's disease.

Abstract: The invention relates to pharmaceutical compositions having casein kinase 1 delta (CK1?) inhibitors and to the use of the inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.

Abstract: The invention relates to pharmaceutical compositions having casein kinase 1 delta (CK1?) inhibitors and to the use of the inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.

Abstract: The invention relates to pharmaceutical compositions comprising casein kinase 1 delta (CK1?) and to the use of said inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.

Abstract: The invention relates to pharmaceutical compositions having casein kinase 1 delta (CK1?) inhibitors and to the use of the inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.

Abstract: The present disclosure provides methods for identifying anthocyanins with improved stability, color, or hue using a screening method, and producing anthocyanins with improved stability, color, or hue in, for example, host cells comprising one or more heterologous glycosyltransferase nucleic acid molecules and one or more heterologous acyltransferase nucleic acid molecules.

Abstract: The invention relates to pharmaceutical compositions having casein kinase 1 delta (CK1?) inhibitors and to the use of the inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.

Abstract: Cycloalkyl amine compounds of Formula (I), wherein ring A is C3-C6 cycloalkyl, optionally substituted with one or more C1-C3 alkyl, and R5 is ORS2, in which RS2 is H or C1-C6 alkyl, or R5 and R6, together with the carbon atom to which they are attached, form C?O, for use in treating CNS disorders, including movement disorders, depressive disorders, sleep disorders, cognitive dysfunctions, obesity, sexual dysfunction and substance abuse.

Abstract: Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to express a mutant AROM polypeptide and/or mutant catechol-O-methyltransferase polypeptide alone or in combination with one or more vanillin biosynthetic enzymes or UDP-glycosyltransferases (UGTs). Such microorganisms, plants, or plant cells can produce vanillin or vanillin beta-D-glucoside.

Abstract: The invention relates to pharmaceutical compositions comprising casein kinase 1 delta (CK1?) and to the use of said inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.

Abstract: The invention relates to pharmaceutical compositions comprising casein kinase 1 delta (CK1?) and to the use of said inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.

Abstract: The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease and diseases involving matrix or cartilate degradation.

Abstract: This method enables computational analysis and manipulation of DNA and protein sequence data such as is found in large public databases. The method allows systematic searches of such data to identify portions of sequences which code for key intermolecular surfaces or regions of specific protein targets. In a first example, two amino acid sequences are input (steps 1, 2) to an iterative procedure (steps 4-6). A frame size is selected in terms of a number of sequence elements. The procedure then compares pairs of frames, one from each sequence, to identify intramolecular and intermolecular regions on the basis of relationships between amino acids according to a predetermined coding scheme. The probability of existence of each region within the coding scheme is then evaluated and those regions for which the probability is greater than a predetermined threshold are discarded. The procedure outputs the remaining regions.

Abstract: In the current invention the application of our novel informatics approach to the databases containing nucleotide and peptide sequences from pathogens generates the sequence of many peptides which form the basis of an innovative and novel approach to developing anti-infective drugs.